Thiocolchicoside Exhibits Anticancer Effects through Downregulation of NF-κB Pathway and Its Regulated Gene Products Linked to Inflammation and Cancer
- 1 November 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 3 (11) , 1462-1472
Abstract
The discovery of new uses for older, clinically approved drugs is one way to expedite drug development for cancer. Thiocolchicoside, a semisynthetic colchicoside from the plant Gloriosa superba, is a muscle relaxant and used to treat rheumatologic and orthopedic disorders because of its analgesic and anti-inflammatory mechanisms. Given that activation of the transcription factor NF-κB plays a major role in inflammation and tumorigenesis, we postulated that thiocolchicoside would inhibit NF-κB and exhibit anticancer effects through the modulation of NF-κB–regulated proteins. We show that thiocolchicoside inhibited proliferation of leukemia, myeloma, squamous cell carcinoma, breast, colon, and kidney cancer cells. Formation of tumor colonies was also suppressed by thiocolchicoside. The colchicoside induced apoptosis, as indicated by caspase-3 and poly(ADP-ribose) polymerase cleavage, and suppressed the expression of cell survival [e.g., Bcl-2, X-linked inhibitor of apoptosis (XIAP), MCL-1, bcl-xL, cIAP-1, cIAP-2, and cFLIP] proteins. Cell proliferation biomarkers such as c-MYC and phosphorylation of phosphoinositide 3-kinase and glycogen synthase kinase 3β were also blocked by thiocolchicoside. Because most cell survival and proliferation gene products are regulated by NF-κB, we studied the effect of thiocolchicoside on this transcription factor and found that thiocolchicoside inhibited NF-κB activation, degradation of inhibitory κBα (IκBα), IκBα ubiquitination, and phosphorylation, abolished the activation of IκBα kinase, and suppressed p65 nuclear translocation. This effect of thiocolchicoside on the NF-κB pathway led to inhibition of NF-κB reporter activity and cyclooxygenase-2 promoter activity. Our results indicate that thiocolchicoside exhibits anticancer activity through inhibition of NF-κB and NF-κB–regulated gene products, which provides novel insight into a half-century old drug. Cancer Prev Res; 3(11); 1462–72. ©2010 AACR.Keywords
This publication has 30 references indexed in Scilit:
- NF-κB and cancer: how intimate is this relationshipMolecular and Cellular Biochemistry, 2009
- Inflammation and cancer: how friendly is the relationship for cancer patients?Current Opinion in Pharmacology, 2009
- RETRACTION: Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid CellsMolecular Pharmacology, 2008
- Clonogenic assay of cells in vitroNature Protocols, 2006
- Transcription Factor NF‐κB: A Sensor for Smoke and Stress SignalsAnnals of the New York Academy of Sciences, 2005
- Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back painInternational Journal Of Clinical Practice, 2005
- New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humansFundamental & Clinical Pharmacology, 2004
- RELevant gene amplification in B-cell lymphomas?Blood, 2004
- Complementation Cloning of NEMO, a Component of the IκB Kinase Complex Essential for NF-κB ActivationCell, 1998
- Single‐dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteersBiopharmaceutics & Drug Disposition, 1994